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Despite advances in surgery, radiation therapy, and chemotherapeutics, patients with malignant glioma have a dismal prognosis.
The formations of aberrant tumour vasculature and glioma cell invasion are major obstacles for eﬀective treatment. Angiogenesis
is a key event in the progression of malignant gliomas, a process involving endothelial cell proliferation, migration, reorganization
of extracellular matrix and tube formation. Such processes are regulated by the homeostatic balance between proangiogenic and
antiangiogenic factors, most notably vascular endothelial growth factors (VEGFs) produced by glioma cells. Current strategies
targeting VEGF-VEGF receptor signal transduction pathways, though eﬀective in normalizing abnormal tumor vasculature,
eventually result in tumor resistance whereby a highly infiltrative and invasive phenotype may be adopted. Here we review recent
anti-angiogenic therapy for malignant glioma and highlight implantable devices and nano/microparticles as next-generation
methods for chemotherapeutic delivery. Intrinsic and adaptive modes of glioma resistance to anti-angiogenic therapy will be
discussed with particular focus on the glioma stem cell paradigm.
1. Introduction
Glioblastoma multiforme (GBM) (WHO grade IV astrocy-
toma) is amongst the most vascular and aggressive of all solid
tumors and continues to have an extremely poor prognosis.
They are the most common primary brain tumor in adults,
with about 4800 new cases each year in the United Kingdom
(∼17500 per year in the USA), comprising approximately
one percent of all tumor diagnoses. The tumor is charac-
terized on histological examination by poorly diﬀerentiated
neoplastic astrocytes, with cellular polymorphism, nuclear
atypia, mitotic activity, necrosis, vascular proliferation and
thrombosis [1]. The tumors are highly infiltrative (though
distant metastasis is rare) and inevitably recur, even after
gross macroscopic surgical resection. However, studies have
demonstrated that complete (>90%) resection is associated
with survival benefit in both adults [2] and children [3].
Current first choice adjuvant therapy in adults subsequent
to maximal surgery is radiation therapy (usually 60 Gy in
30 fractions) with concomitant temozolomide, an alkylating
agent. This regime has shown a significant survival benefit
[4], extending median survival from 12.1 to 14.6 months.
Although a significant improvement, the long-term survival
of these patients is still extremely limited with only 8%
surviving for four years (compared to zero survivors in the
radiotherapy only arm).
In childhood, low-grade astrocytomas are the most com-
mon tumor type with high-grade gliomas (HGG) making up
10%–15% of tumors diagnosed [5], a total of around 50–70
cases per year in the U.K. Paediatric central nervous system
tumors however account for more expected life years lost
than any other tumor group and are now the leading cause
of cancer deaths in children, following improvements in sur-
vival rates for the leukemias. Treatment broadly follows adult
regimes with surgery and radiotherapy being accompanied
by alkylating agents. Comparatively, little research has been
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performed in children regarding therapy and the molecular
genetics of high-grade glioma, and although pediatric HGG
may resemble adult GBM on histopathological criteria, there
are significant diﬀerences both clinically and within the
molecular biology of the tumors. Long-term survival is more
frequent in children, especially those under three years old
and it may be that radiotherapy can be avoided in this
age group [6]. All modalities of treatment have potentially
devastating side eﬀects, often resulting in severe neurological
disability. Pathways controlling the generation of new blood
vessels (angiogenesis) are frequently implicated in both
adult and pediatric tumors. Many genome wide studies
have implicated proangiogenic pathways including vascular
endothelial growth factor (VEGF) [7], epidermal growth
factor (EGF) [8], and platelet-derived growth factor (PDGF)
[9]. HGG are in general extremely vascular tumors with
evidence of widespread production of new blood vessels.
Eﬀorts are currently underway to target these pathways
therapeutically with the hope of developing eﬀective novel
treatments for HGG that are better tolerated than current
cytotoxic chemotherapy.
It is clear that novel therapies are needed for this
tumor to improve the current situation. Here we evaluate
current antiangiogenic therapies (summarized in Table 1)
and mechanisms of resistance for malignant glioma and
consider the development of novel methods of drug delivery
to overcome the problem of achieving therapeutic drug
concentrations within the CNS caused by the impermeability
of the blood brain barrier (BBB).
2. Glioma Angiogenesis and Invasion
Glioma vasculature formation occurs through two distinct
processes. Glioma angiogenesis is a process involving the
genesis of new blood vessels from rerouting and remodeling
of preexisting vessels. Neoangiogenesis mainly develops in
late embryonic development and during adulthood as a
result of tissue demands [10]. Vasculogenesis (blood vessel
arrangement) was classically considered an embryonic pro-
cess but has since been identified in tumors as the de novo
formation of primitive blood vessels by the diﬀerentiation of
circulating bone marrow-derived endothelial progenitor cells
[11]. Among solid tumors, glioblastoma multiforme displays
the most angiogenic features and highest degree of vascular
proliferation and endothelial cell hyperplasia [12]. Angio-
genesis is thus a key pathologic event in glioblastoma tumors
and is necessary for the progression of a localized neoplasm
to a highly aggressive tumour. Moreover, malignant gliomas
also require angiogenesis to establish a source of nutrients
and oxygen and to eliminate cellular waste products [13].
2.1. The Molecular and Cellular Angiogenic Switch. Glioma
angiogenesis is initiated when the homeostatic balance
between pro-angiogenic and anti-angiogenic stimuli is dis-
rupted in favor of the former, resulting in activation of pro-
angiogenic signaling pathways. These stimuli are secreted
by both cellular sources (glioma cells, endothelial cells and
microglia) and environmental triggers (extracellular matrix
(ECM), hypoxia) [14, 15]. The transition towards neo-
angiogenesis is referred to as the “angiogenic switch” and
is increasingly viewed as a rate-limiting secondary event in
multistage carcinogenesis [16].
The initial stage in the formation of new blood vessels
involves the breakdown of native vessels. Angiopoietin-1
(Ang-1) and its receptor Tie-2 are key components of this
process and Ang-1 is increased in GBM tumor cells [17,
18]. Glioma cells first accumulate around existing cerebral
blood vessels and lift oﬀ astrocytic process, leading to the
disruption of normal contact between endothelial cells and
the basement membrane [18]. Subsequently, these blood
vessels become apoptotic and undergo involution. Vascular
collapse ensues and results in the death of neighboring tumor
cells and the formation of necrotic zones. Hypoxia arises in
these regions resulting in expression of hypoxia inducible
factor-1 (HIF-1). In GBMs, HIF-1α is primarily localized
in pseudopalisading cells around areas of necrosis and in
tumor cells infiltrating the brain at the tumor margin [19].
HIF-1α is a transcriptional master regulator that activates a
plethora of genes, the protein products of which function
to either increase oxygen availability or to allow metabolic
adaptation to oxygen deprivation [20]. In this context, HIF-
1α transcriptionally activates VEGF which in turn initiates
and promotes glioma angiogenesis (see Mediators of glioma
angiogenesis below) [21, 22].
Following regression of native blood vessels, the
basement membrane and surrounding ECM are degraded
to allow for endothelial cell invasion. The matrix-
metalloproteinases (MMP)-2 and 9 are major factors for
this event in brain tumor angiogenesis and MMP-2 and
MMP-9 expression is associated with a poor outcome in
glioma patients [23, 24]. Upon breakdown of the basement
membrane, endothelial cells proliferate and migrate toward
tumor cells that express pro-angiogenic factors. Activation
of endothelial cells results in upregulation of cell surface
adhesion/migration molecules, in particular αvβ3, α5β1, and
CD44 [25].
2.2. Pro-Angiogenic Mediators in Glioma
2.2.1. Vascular Endothelial Growth Factor. The VEGF family
of growth factors and their receptors are the most important
mediators of glioma angiogenesis. VEGF ligands (VEGF-A,
VEGF-B, VEGF-C, VEGF-D, and placenta growth factor)
bind to and activate the VEGF receptor (VEGFR) tyrosine
kinases (VEGFR-1 and VEGFR-2). Specifically, VEGF-A is
upregulated in glioblastoma and regulates endothelial cell
survival, proliferation, vascular permeability, and migration
primarily via VEGFR-2 [26, 27]. VEGF-A is primarily
induced by tissue hypoxia via the HIF-1α pathway. The
hypoxic microenvironment leads to dissociation of von Hip-
pel Lindau protein from HIF-1α, preventing its proteasomal-
mediated degradation and permitting HIF-1α binding to
hypoxia response elements in the promoter region of several
pro-angiogenic factors, such as VEGF [28]. In addition to
HIF-1α, a variety of growth factors can also upregulate
VEGF expression, including transforming growth factor
(TGF)-β, EGF, PDGF-B, and basic fibroblast growth factors
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(FGF) [29–31]. The end result of VEGF signaling in the
glioma neovascular niche is the production of immature
highly permeable blood vessels with poor maintenance
of the blood brain barrier and parenchymal edema [32].
VEGF also functions as a prosurvival factor for endothelia,
mediated by suppression of p53, p21, p16, and p27, Bax pro-
apoptotic protein and activation of phosphatidylinositol-3
kinase (PI3K)/Akt and Ras/mitogen activated protein kinase
(MAPK) pathways [33, 34].
2.2.2. Fibroblast Growth Factor. Similar to VEGF, fibroblast
growth factor (FGF) is expressed by glioma cells and their
adjacent blood vessels [9]. FGF-receptor 1 is upregulated in
endothelial cells while FGF-receptor 4 is expressed primarily
in tumor cells [35, 36].
2.2.3. Platelet-Derived Growth Factor. In addition to
endothelial cell migration, pericyte (mesenchymal-like cells,
associated with the walls of small blood vessels) migration
is an important part of the process of tumor vasculogenesis
[37]. PDGF secretion by activated endothelial cells recruits
pericytes to the site of newly formed vessels and contributes
to the development of a new basement membrane [38].
Of the two PDGF tyrosine kinase receptors (PDGF-α and
PDGF-β), PDGF-α is expressed in an autocrine manner
in glioma cells, whereas PDGF-β is expressed in glioma
endothelium and pericytes, particularly the latter, suggesting
its importance in the migration of pericytes into newly
formed blood vessels [39].
2.2.4. Tumor Necrosis Factor. Tumour necrosis factor (TNF)-
α is a potent inflammatory cytokine found in malignant
gliomas and other cells including reactive astrocytes. TNF-
α induces tumor angiogenesis indirectly via the activation
of other angiogenic factors, most notably VEGF [40].
Furthermore, VEGF is upregulated in human gliomas upon
TNF-α treatment, mediated through the Sp1 transcription
factor [41].
2.2.5. Integrins. Integrins are transmembrane receptor
molecules that facilitate endothelial cell migration and
invasion and specifically, integrin-αvβ3 correlates to glioma
tumor grade and glioma cell proliferation [42, 43].
2.2.6. Matrix Metalloproteinases. MMP-2, and MMP-9 are
highly expressed in astrocytomas and correlate with his-
tological grade. Both proteins are detected in tumor and
endothelial cells [44]. MMPs are involved in the prote-
olytic degradation of ECM components and facilitate cell
motility during angiogenesis [45]. Upregulation of MMPs
is required for the angiogenic eﬀects of TGF-β and VEGF
and MMP-2 and MMP-9 proteolytically cleave and activate
TGF-β, thus promoting tumour invasion and angiogenesis
[46, 47].
Table 1: Anti-angiogenic agents trialled in high-grade glioma and
their respective targets.
Antibody Therapies Major Molecular Targets
Bevacizumab Free VEGF-A
IMC-3G3 PDGFR alpha
Ramucirumab VEGFR-2
Nimotuzumab EGFR
AMG-102 Hepatocyte Growth Factor
VEGF-trap Decoy receptor for VEGF
Tyrosine Kinase Inhibitors
Cediranib VEGFR/PDGFR/c-Kit
Sorafenib VEGFR/PDGFR/c-Kit/Raf
Sunitinib VEGFR/PDGFR
AE788 EGFR/VEGFR
Erlotinib EGFR
Imatinib PDGFR/Bcr-abl/c-Kit
Dasatanib Src kinases
Signal Pathway Inhibitors
Enzastaurin Protein Kinase C
Rapamycin/Temsirolimus mTOR
Tipifarnib Ras
Other Agents
Thalidomide/Lenalidomide NO/TNF alpha/IL-6
Celecoxib Endostatin
Cilengitide Integrins αvβ3 and αvβ5
2-methoxyestradiol HIF1α
Prinomastat MMPs 2,9,13 and 14
SAHA(Vorinostat) Histone deacetylase
2.2.7. AntiAngiogenic Mediators in Glioma. A number of
anti-angiogenic factors have been described and are func-
tionally relevant to tumor angiogenesis. Angiostatin is
derived from degradation of plasminogen by proteases such
as cathepsin D and MMPs and functions as an endogenous
anti-angiogenic factor [48]. Murine models reveal that
angiostatin impairs glioma angiogenesis and tumor growth
through binding of αvβ3 on proliferating endothelial cells,
resulting in apoptosis [49, 50].
The thrombospondins (TSPs) are another family of
proteins that function as anti-angiogenic factors. TSP-1 is
expressed on platelets, endothelial cells and smooth muscle
cells in normal tissue [51]. TSP-1 reduces endothelial cell
proliferation and induces apoptosis in vitro [52], TSP
peptides derived from TSP-1 decrease glioma angiogenesis
and tumor growth in mice [53].
Endostatin is a similar anti-angiogenic molecule, formed
by proteolytic cleavage of collagen-18 in glioblastoma base-
ment membrane by elastase, cathepsin-L and specific MMPs
[54]. Endostatin-mediated angiogenesis blockade includes
binding to α5β1 integrin, inhibition of VEFGR-2, and
decreased expression of the anti-apoptotic molecule, Bcl-2
[55].
2.3. Glioma Invasion. Animal models of glioma invasion
fail to accurately mimic the invasiveness of human glioma
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cells along white matter tracts. Alternative models such
as matrigel invasion chambers and xenograft lines serially
passaged in vivo have therefore been more informative
for study. Glioma cell invasion requires four distinct pro-
cesses: (i) detachment of invading cells from the primary
tumor mass, involving destabilization and disorganization
of cadherin-mediated junctions, downregulation of neural
cell adhesion molecule and CD44 cleavage which anchors
the primary mass to the ECM by the metalloproteinase
ADAM; (ii) adhesion to the ECM, mediated by integrins,
particularly αvβ3 which binds fibronectin in the ECM; (iii)
degradation of the ECM by proteases such as MMP-2 and
MMP-9; and (iv) cell motility and intracellular contractility,
mediated by cytoplasmic mediators such as myosin [10].
Invasion along white matter tracts allows gliomas to extend
at a microscopic level beyond surgical resection cavities
or radiation treatment fields [56]. Glioma cells migrate in
a similar fashion to nontransformed neural progenitors,
whereby a prominent leading cytoplasmic process is followed
by a burst of forward movement by the cell body. This
raises the intriguing question of whether stem/progenitor-
like cells in glioma have a causative role in glioma invasion,
migration and metastases. Indeed glioma stem (or stem-
like) cells are highly invasive and are able to invade across
the corpus callosum along white matter tracts [57, 58].
Such stem cell models may contribute significantly to future
glioma invasion models.
3. Anti-Angiogenic Therapies
3.1. Antibody Therapies. One of the most well-established
anti-angiogenic therapies is bevacizumab (Avastin, Roche).
This is an IgG1 monoclonal antibody against free VEGF-A
in the circulation, to which it binds, preventing attachment
to the VEGF receptor and activation of a pro-angiogenic
stimulus. Bevacizumab was originally developed for use in
metastatic colorectal and nonsmall cell lung cancers, and has
subsequently also been approved by the European Medicines
Agency for use in metastatic breast and kidney cancers [59].
In view of the high levels of new vessel formation in GBM,
many groups have now used bevacizumab for the treatment
of this tumor, often in combination with irinotecan (a
topoisomerase inhibitor).
There are currently two phase III trials (NCI and
Hoﬀman La Roche) recruiting newly diagnosed glioblas-
toma patients for double-blind placebo-controlled studies
comparing surgery, radiotherapy and temozolomide with
or without bevacizumab, results of which will be of huge
interest.
Phase two trials in patients with recurrent disease have
yielded very encouraging results [60] with 6-month progres-
sion free survival (PFS) rates of 46% and 6-month overall
survival (OS) rate of 77% (n = 35 patients) for bevacizumab
plus irinotecan in GBM [61]. The same group demonstrated
6-month PFS and OS of 55% and 79%, respectively, for
the same agents in recurrent anaplastic astrocytoma (WHO
grade III glioma) [62]. Radiological response rates were
reported as 57%–63%. Similar response rates have also been
observed by other groups in small scale series [63, 64]. As a
comparator for this and other trials described, the six-month
progression free survival for temozolomide as monotherapy
in relapsed GBM has been reported as 21% [65].
Although initial response rates in the desperate situation
of recurrent GBM are encouraging, it is clear that this
response is temporary, and tumors eventually progress
regardless. Attempts to modify bevacizumab regimes with
second agents introduced at progression have not proved
successful with 6-month PFS of 0%–2% [60, 66]. A particular
concern with antibody therapy is its ability to cross the
BBB. Clearly bevacizumab may be eﬀective at reducing VEGF
levels within the circulating volume, but it has not yet been
demonstrated what eﬀect it may have on paracrine VEGF
pathways within the tumor and brain parenchyma itself, as
it is probably unable to cross the BBB, although this barrier
may be deficient in tumors.
Bevacizumab is in general well tolerated with few serious
side eﬀects, with approximately 10% of patients having to
discontinue treatment in the trials to date. Serious side eﬀects
reported include intracerebral haemorrhage, bowel perfo-
ration, and thromboembolism. Predicting patients likely to
respond to a particular therapy is an area likely to be of
increasing significance as more therapies are developed, and
more is known of the molecular biology of these tumors. One
trial to date has reported that high immunohistochemical
VEGF A expression was significantly associated with like-
lihood of radiographic response, but not overall survival
[67]. VEGF single nucleotide polymorphisms may also be
indicative of response rates [68].
It has been reported that recurrence after bevacizumab
therapy is more likely to be diﬀuse and distant to the
primary tumor location [64, 69]. One possible concern is
that the therapy could be inducing increased cell migration
within the tumor to escape from areas of hypoxia created by
the drug. This diﬀuse infiltration may not be immediately
obvious on conventional gadolinium-enhanced MRI and
novel MRI techniques may be required to investigate this
phenomenon [70]. It is unclear whether enlarging areas of
T2 hyperintensity truly represent tumor invasion or simply
increasing edema, with mismatch of clinical and radiological
pictures [59].
A similar approach to bevacizumab is VEGF-Trap
(Aflibercept—Sanofi/Regeneron). This is a fusion protein
soluble decoy receptor with a high aﬃnity for VEGF A [71]. It
has been shown in animal glioma models to have significant
antitumor activity [72], and phase I/II human clinical trials
are underway (NCI).
Early stage trials (NCI) are being undertaken into other
monoclonal antibodies directed against PDGFRα (IMC-
3G3) or VEGFR-2 (ramucirumab), which seems to show
promise in early trials in other malignancies [73]. A
German randomised controlled trial of nimotuzumab (an
EGFR receptor antibody) in newly diagnosed glioblastoma
is ongoing. This antibody, along with the similar anti-
EGFR antibody cetuximab, has been shown to radiosensitise
glioma cells in a mouse model, with nimotuzumab having
increased anti-angiogenic and antiproliferative eﬀects [74].
AMG 102 (an antihepatocyte growth factor antibody) has
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shown promising eﬀects in vitro in combination with an
anti-EGFR antibody [75].
3.2. Small Molecule Inhibitors. In recent years, there has
been much interest in developing inhibitors of various
components of the angiogenic pathway. Many of these
compounds are of relatively low molecular weight, allowing
improved penetration of the BBB and the cytoplasm or
nucleus of cells. However, they may still be targeted by
drug extrusion systems (e.g., PGP or MDR) and intracellular
concentrations may be lowered as a result. In this way,
precise molecular targets can be modulated, with the hope
of eﬃcacious anti-angiogenic therapy with minimal eﬀect
on normal nonangiogenic tissue. The compounds of this
type are also usually able to be taken orally, with good
tolerability in most trials to date. Agents have been or are
in the development process for many molecular targets and
they will be summarised here. Many of the small molecule
inhibitors act on, for example, multiple molecularly related
receptor tyrosine kinases. This may have some advantages in
allowing targeting of entire angiogenic pathways, potentially
more eﬀective than simply targeting single growth factors or
receptors.
3.3. Vascular Endothelial Growth Factor Inhibitors. In addi-
tion to antibody-based approaches targeting free VEGF,
compounds have been developed to target the functioning
of the VEGF receptor. An example of this class is cediranib
(Recentin/AZD2171—Astra-Zeneca). This is an indole-ether
quinazoline that inhibits tyrosine kinase receptors, partic-
ularly all subtypes of the VEGF receptor, and has some
activity against the PDGF and c-Kit receptors. A phase II
trial of cediranib showed a radiological response rate of 56%,
with 6-month PFS of 26% in recurrent glioblastoma [59].
The same trial [76] also demonstrated that after just one
day of cediranib treatment, magnetic resonance imaging can
demonstrate changes in vascular permeability and flow using
Ktrans type techniques. Microvessel volume decreased back
towards normal values and these changes were maintained
until around the 56 day scan. When the authors com-
bined measures of permeability, microvessel volume, and
circulating IV collagen, the “vascular normalisation index”
created was an excellent predictor of response and overall
survival [77]. The same study also demonstrated reduction
in the number of viable circulating endothelial cells and
circulating progenitor cells which increased in number when
the tumors progressed or relapsed. As well as decreasing
new vessel formation, it is hypothesised that the process of
normalisation of already formed vessels may enhance the
eﬀect of radiotherapy by reducing hypoxia and may enhance
the delivery of other chemotherapeutic agents to the tumour.
Strategies to extend this window of normalisation before the
tumour begins to revert may need to be explored.
Sorafenib (Nexavar—Bayer/Onyx) inhibits a broad range
of kinases including serine/threonine and receptor tyrosine
kinases. Pathways known to be inhibited by this drug
include VEGFR, PDGFR-β, c-Kit, and their downstream
eﬀectors C-Raf and B-Raf kinases. This in turn leads to
decreased MEK 1, 2, ERK and MAPK activity, pathways
implicated in cell proliferation as well as angiogenesis
[78]. Sorafenib in combination with bortezomib [32] (a
proteasome inhibitor) or rottlerin [79] (a protein kinase C
inhibitor) has demonstrated eﬃciency against glioma cell
lines, and several phase I/II trials are underway in both newly
diagnosed and recurrent GBM. The drug has already been
approved for use in renal cell carcinoma, and in common
with other anti-angiogenic therapy, hypertension and fatigue
are not uncommon side eﬀects. Perhaps of greater concern
is the risk of intracerebral haemorrhage which has been
reported as higher than usual in patients with renal cell
carcinoma cerebral metastases treated with VEGF inhibitors
[80].
Sunitinib (Sutent—Pfizer) is an inhibitor of VEGF and
PDGF-β receptors which has also been used with some
success in metastatic renal cell carcinoma. It has demon-
strated eﬃcacy in reducing new blood vessel formation, with
corresponding survival benefit in both subcutaneous and
intracerebral murine glioma models [81] and is currently
undergoing phase I/II trials in recurrent GBM in humans.
Although a potent inhibitor of angiogenesis, and demon-
strating beneficial eﬀects in many animal models, some
studies have demonstrated an apparent increase in metastatic
behavior of tumors under certain situations, perhaps due
to a preconditioning eﬀect on the tumor microenvironment
[82, 83]. These findings may echo the increased T2 signal
change seen in GBM patients treated with VEGF inhibitors.
AEE788 (Novartis) is an inhibitor of EGFR, and at higher
concentrations, VEGFR. This agent had also shown promise
in mouse xenograft models when used in combination with
everolimus [84], an mTOR pathway inhibitor related to
rapamycin (sirolimus). Phase I/II clinical trials are underway
currently in recurrent GBM, but further development may be
suspended. Other agents being investigated include vatalanib
and pazopanib, both VEGF inhibitors with some anti-PDGF
activity.
3.4. Other Tyrosine Kinase Inhibitors. In addition to
the VEGF inhibitors described with anti-PDGF activity,
molecules have been developed specifically targeting the
PDGF receptor and pathway. The most widely used of these
is imatinib (Glivec—Novartis), a small molecule tyrosine
kinase inhibitor active against PDGF, Bcr-abl, and c-Kit.
Although well tolerated, single agent imatinib had very
limited eﬀect against high-grade glioma in adults, particu-
larly in patients on anticonvulsants [85, 86]. Trials are now
being undertaken to ascertain whether more eﬀective results
can be obtained by the use of imatinib in combination
regimes, for example, with vatalanib [87] or temozolo-
mide. Dasatanib, another multikinase inhibitor targeting Src
kinases, is currently in early stage clinical trials and has
shown promising antiglioma eﬀect in vitro, particularly in
combination with temozolomide [88]. NCI phase II studies
of another multikinase inhibitor tandutinib are currently
ongoing, one in combination with bevacizumab.
Erlotinib (Tarceva—OSI/Roche), is a selective EGFR
antagonist that has been used in lung cancer. A phase II study
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has shown very promising results with median survival of
19.3 months after diagnosis, compared to 14.1 months for
historical controls [89], though a phase II trial of its use as
monotherapy in recurrent GBM was disappointing [90]. Sev-
eral further trials are ongoing, including in conjunction with
bevacizumab. Gefitinib (Iressa—Astra Zeneca) is another
selective EGFR antagonist that binds the ATP binding site
of the EGF receptor. Disappointing results in the ISEL lung
cancer trial [91] led to it being partially withdrawn in the
United States, but hopes remain that a subset of patients with
tumours containing appropriate EGF pathway mutations
may have some benefit. Studies are ongoing in glioma,
especially of its use in combination with other therapy, for
example, everolimus [92], though a phase II trial showed
limited benefit as monotherapy in recurrent GBM [93].
Other drugs developed to inhibit downstream kinases
include enzastaurin (Eli Lilly) a selective protein kinase C β-
inhibitor which suppresses phosphorylation of many targets
including Akt, inhibiting development of xenografted glioma
[94]. A phase I trial has showed some promising eﬀects,
although dosage was limited by thrombocytopenia and pro-
longed QT syndrome [95]. The mTOR pathway has also been
targeted therapeutically, initially as immunomodulatory
therapy for prevention of transplant rejection, but interest
in its antineoplastic properties has increased in recent years.
This pathway is of interest as it integrates multiple upstream
cell signalling mechanisms to regulate protein synthesis,
potentially allowing the eﬀects of multiple growth factor
receptors to be controlled. Rapamycin (Sirolimus—Wyeth)
is a macrolide produced by the bacterium Streptomyces
hygroscopicus that was originally isolated from soil samples
from the island of Rapa Nui (Easter Island). It binds FKBP12
and this combination then inhibits the mTOR pathway.
Rapamycin and its analogues temsirolimus and everolimus
are currently undergoing phase I/II clinical trials, both as
mono- and combination therapy. Temsirolimus has shown
promise in published clinical trials, with extended time to
progression [96].
3.5. Other Agents. Thalidomide (Celgene), a piperidinyl
isoindole, has a broad spectrum of anti-angiogenic mech-
anisms, possibly including suppression of endothelial cell
nitric oxide-induced migration, inhibition of TNFα and
VEGF/IL-6 suppression [97]. In phase II clinical trials, the
results have been somewhat mixed, with some groups report-
ing encouraging outcomes [98, 99], but others showing
limited activity [100]. The addition of thalidomide and the
cyclo-oxygenase-2 inhibitor celecoxib (shown to decrease
angiogenesis in vitro through up regulation of the endoge-
nous inhibitor endostatin) to temozolomide did not improve
progression free survival [101]. The use of thalidomide can
be limited by adverse eﬀects such as thrombosis or peripheral
neuropathy and analogues have been developed such as
lenalidomide [102].
Cilengitide (EMD pharmaceuticals) is a cyclic arginine-
glycine-aspartic acid peptide that selectively inhibits inte-
grins αvβ3 and αvβ5. In a phase II trial, the higher dose regime
demonstrated a 6 month PFS of 15% in recurrent GBM
[103] and trials are ongoing for its use in combination with
temozolomide in newly diagnosed GBM. Other potential tar-
gets are the HIFs, which upregulate pro-angiogenic cellular
factors in response to low-tissue oxygen partial pressure. The
oestrogen derivative 2-methoxyestradiol (2ME2/Panzem—
EntreMed) inhibits HIF1α mediated VEGF expression and
directly downregulates HIF1α levels, as well as suppressing
microtubule structure formation [97]. Clinical trials of
2ME2 in association with nanocrystal colloidal dispersion
are ongoing. Research interest has also focused on attempts
to inhibit matrix metalloproteinases (MMPs), important
mediators of new vessel growth and tumour invasion.
Prinomastat (Agouron) is a hydroxamate-based selective
inhibitor of MMPs 2, 9, 13, and 14, which had mixed results
in clinical trials in lung cancer [103], with trials in GBM
completing at present. Farnesyl transferase inhibitors such
as tipifarnib (Zarnestra—Johnson & Johnson) block the
farnesylation of the Ras signalling molecule that is needed
for it to fulfil its downstream eﬀects in the signalling cascade
that occurs after activation of growth factor receptors. Whilst
evidence of benefit has been reported in one phase II trial
[104], another found no benefit when given as preradiation
sensitizer [105].
Histone deacetylase inhibitors (HDACi) are emerging
as a promising class of anticancer agent, which act by
alleviating transcriptionally silenced pathways in tumors,
such as tumor suppressor pathways. HDACi have also been
shown to possess antiinvasive and anti-angiogenic potential
with SAHA/vorinostat currently undergoing phase II trials
for recurrent GBM [106–108]. Although it is unclear whether
these compounds have anti-angiogenic eﬀects in glioma,
we have revealed anti-proliferative and pro-apoptotic eﬀects
using the HDACi Trichoststin A in pediatric glioblastoma
cells (R. Rahman, manuscript in preparation).
3.6. Pediatric Tumours. Very few trials of anti-angiogenic
therapy have been performed in pediatric high-grade glioma.
As previously stated, this is unfortunate as it is increasingly
clear that it may not be possible to extrapolate results from
adult trials to pediatric practice as genome wide studies
indicate that there may be key diﬀerences in the molecular
biology of HGG in diﬀerent age groups.
Chemotherapy administered to children has often been
performed in a metronomic fashion with the intention
of targeting the tumor endothelium, and studies utilising
thalidomide have been undertaken, with a subset of patients
having prolonged PFS [109]. A phase I study of cilengitide
demonstrated good response in patients completing the
treatment and a phase II study is planned. Erlotinib has
been evaluated in a phase I trial in children, adolescents, and
young adults with newly diagnosed HGG [110], with evalu-
ation proceeding. A phase I trial of imatinib in children with
newly diagnosed brainstem and recurrent malignant gliomas
showed some concerns with intratumoral haemorrhage and
dose limiting toxicity in patients with brain stem glioma but
seemed well tolerated in recurrent glioma [111]. Tipifarinib
has been used in a phase I trial in brainstem glioma [112]
and a phase II trial in several high-grade brain tumours
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with good tolerability but little eﬀect [90]. A phase I trial of
semaxanib (SU5416) was terminated early due to the sponsor
ceasing development of the drug, although prolonged disease
stabilisation was seen in 25% of patients given the higher
dosage [113].
4. Mechanisms of Glioma
Anti-Angiogenic Resistance
Benefits of anti-angiogenic therapy both in preclinical set-
tings and to patients are at best transitory, typically in the
form of tumor stasis or shrinkage and in few cases, increased
survival. Inevitably this period of clinical benefit (measured
in weeks/months) is followed by restoration of tumor growth
and progression [114]. Indeed, inhibiting VEGF does not
appear to block tumour progression. Such resistance to anti-
angiogenic therapy is counter-intuitive to the proposition
that angiogenesis is essential for the progression of malignant
glioma. Knowledge of the mechanistic basis governing anti-
angiogenic resistance is required to fine-tune and better
specify future treatment protocols using these drugs. The
current status quo proposes two general modes of resistance
to angiogenesis inhibitors, particularly those targeting VEGF
and related pathways: adaptive (evasive) resistance, and
intrinsic (preexisting) resistance (Figure 1) [115]. Multiple
mechanisms are likely to underlie both modes of resistance.
4.1. Adaptive (Evasive) Resistance. An evolving hypothesis is
that angiogenic tumors acquire the means to functionally
evade the angiogenesis blockade induced by angiogenesis
inhibitors [116–119]. Evasive resistance is indirect in so
much as alternative means to sustain tumor growth are
activated but the specific therapeutic target of the anti-
angiogenic agent remains inhibited (Figure 1, top) [119].
Activation and/or upregulation of alternative pro-angiogenic
signaling pathways may be one distinct adaptive mechanism,
whereby substitution of a pro-angiogenic factor reestab-
lishes neovascularization [120]. Evidence for FGF-dependent
revascularization has come from a clinical investigation
of glioblastoma patients being treated with the VEGFR
inhibitor cediranib. After a measureable response phase, a
relapse/progression phase was associated with higher blood
levels of FGF2 compared to the same patients during the
response phase [76]. Evaluation of the prevalence of this
mechanism in human gliomas would be greatly facilitated
by studying tissue obtained from patients undergoing re-
resection subsequent to recurrence after anti-angiogenic
therapy.
Recruitment of vascular progenitor cells and pro-
angiogenic monocytes from the bone marrow is another
distinct mechanism of resistance. Anti-angiogenic therapy-
induced blood vessel regression may lead to hypoxia, creating
conditions permissive for the recruitment of a heterogeneous
population of bone marrow-derived monocytic cells that
promote angiogenesis [115]. Specifically, these cells consist
of endothelial and pericyte progenitors which diﬀerentiate
into endothelial cells forming the inner lining of blood
vessels, or pericytes that envelop blood vessels, respectively
[121]. In GBM, HIF-1α recruits various pro-angiogenic bone
marrow-derived CD45+ myeloid cells, and tumors lacking
HIF-1α exhibit few such cells and are severely impaired
in their angiogenic and tumor growth phenotypes [122].
These studies provide a mechanistic rationale for how
hypoxic tension can create an environment that promotes
neovascularization.
Although inhibition of VEGF signaling pathways causes
vessel regression, a few thin vessels remain, densely and
tightly covered with pericytes. Protective coating by pericytes
presumably helps the tumor endothelium to survive and
grow during the course of any anti-angiogenic therapy
regime [121]. The contribution of this mode of resistance in
GBM is undefined at present.
The switch to a condition of increased invasiveness with-
out angiogenesis is another method of evasive adaptation.
This phenotype was first described in orthotopic GBM
mouse models, where neovascularization was blocked by
genetically deleting VEGF and HIF-1α. GBM cells coopted
normal blood vessels (perivascular invasion) to achieve the
required vasculature in a dispersed fashion [123].
4.2. Intrinsic (Cellular) Resistance. A considerable minority
of GBM patients tested in clinical trials for bevacizumab,
sorafenib, and sunitinib failed to show even transitory
clinical benefit [76]. As no period of tumor stasis was
evident, these tumors are refractory to angiogenic therapy.
It is plausible that the preexistence of FGF2 and other pro-
angiogenic factors in late-stage GBM tumors could enable
continued angiogenesis using redundant pathways during
anti-angiogenic treatment.
Of particular interest is the glioma cell-type that
is nonresponsive to anti-angiogenic therapy (and other
chemotherapeutics). The stem cell paradigm for malig-
nant gliomas presents tumour-initiating events as occurring
within the genome of a cellular entity with intrinsic or
acquired stem/progenitor cell-like properties. Glioma stem
cells (GSC) have been reported to promote angiogenesis
and vasculogenesis via increased expression of VEGF and
stromal-derived factor 1 [124, 125]. Tumors enriched for
GSCs showed increased vessel density, increased endothelial
cell proliferation and tubule formation, increased endothelial
progenitor mobilization, and recruitment of bone marrow-
derived cells [125]. Although it may be counter-intuitive
to expect GSCs, which by definition represent a very small
minority of glioma tumor cells, to make a meaningful
contribution to glioma angiogenesis, it is important to
note that during early tumor-initiation or the seeding of
a metastatic lesion, the GSC fraction would constitute a
much greater proportion of the tumor mass. Therefore, it
is conceivable that GSCs provide the necessary signals to
trip the angiogenic switch early during the tumor growth
of primary and/or metastatic tumors. Moreover, the hypoxic
microenvironment has recently been shown to promote the
expansion of GSC populations and promote a more stem-like
phenotype in nonstem cell glioma populations [126, 127].
Regardless of whether the glioma cell of origin is a
tissue-specific stem/progenitor cell or the specificity of
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Intrinsic (cellular) resistance
Adaptive (evasive) resistance
- Alternative pro-angiogenic signalling
- Recruitment of bone marrow-derived cells
- Increased pericyte coverage
- Increased glioma cell invasiveness
Anti-VEGF therapy
Transitory response
Relapse
Primary glioma mass
Non-responsiveness
- Redundant pro-angiogenic signalling
- Multi-drug resistance
- Cellular quiescence
Figure 1: Mechanisms of glioma resistance to anti-angiogenic therapeutic modalities. (Top) Adaptive (evasive) resistance. After an initial
transitory response phase, the tumor switches to mechanisms that induce neovascularization and renewed tumor growth and progression,
thereby evading therapeutic blockade. These consist of pro-angiogenic factor substitution (typically dependence on FGF and angiopoietin
signalling in cases of VEGF blockade), recruitment of endothelial cells and pericytes from the bon-marrow, protection of existing tumor
blood vessels via increased pericyte coverage and increased tumor cell invasiveness whereby tumor cells invade adjacent normal tissue
to achieve vascular suﬃciency. (Bottom) Intrinsic (cellular) resistance. From the outset, some gliomas are nonresponsive to angiogenesis
blockade. This may be accounted for by the preexistence of multiple redundant pro-angiogenic signals, which would allow for continued
angiogenesis during anti-angiogenic insults. In addition, glioma stem cells (GSCs) (green circles) have been identified as key mediators of
glioma angiogenesis and may share intrinsic cell survival and lifespan prolonging characteristics with normal tissue stem cells. Specifically,
GSCs may reside in a noncycling quiescent state, thus blocking entry of drugs through the tumor cell membrane and may express relatively
high levels of ABC-drug transporters, enabling a multi-drug resistance phenotype via eﬄux of drugs from the tumor cell. Red lines, tumor
blood vessels.
cell surface antigens in delineating tumor-initiating glioma
cells, the evidence that a subpopulation of glioma cells
shares certain cardinal properties of stem cells and early
progenitors (namely capacity for self-renewal and multi-
lineage diﬀerentiation) provides a conceptual and technical
framework in which to understand cellular resistance to
therapies such as anti-angiogenic agents. It is logical to
query whether surviving glioma cells intrinsically resistant to
angiogenic therapy share characteristics with normal tissue
stem cells which permit a long lifespan, such as cellular
quiescence, expression of ATP-binding cassette (ABC) drug
transporters, and increased DNA repair capacity.
Malignant gliomas that are resistant to chemotherapeu-
tics often display a multidrug resistance phenotype due to
reduced cellular drug accumulation through ABC membrane
eﬄux pumps [128]. In addition, tissue stem cells generally
reside in the G0 stage of the cell cycle and are only
induced to activate self-renewal and diﬀerentiation programs
when the respective tissue needs to be repopulated. It is
possible that the expression of ABC transporters and the
quiescent state of malignant GSCs may be key determinants
of intrinsic nonresponsiveness to anti-angiogenic therapies,
by the extrusion of agents from the cell, and by providing a
barrier for entry of agents into the cell, respectively (Figure 1,
bottom). In addition, studies have shown that GSCs promote
radioresistance by preferential activation of the DNA damage
response [124].
A number of caveats for these hypotheses emerge how-
ever. The expression profiles of drug resistance-related ABC
transporters did not diﬀer between primary and secondary
glioblastomas and no correlation to recurrent tumors was
evident [128]. Moreover, glioma cell populations sorted
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for the expression of the ABCG2-transporter, revealed that
both ABCG2+ and ABCG2− populations exhibited similar
tumorigenicity [129]. Regarding the noncycling nature of
GSCs, direct evidence for the prevalence of quiescence
in glioma is lacking. Through studies of stem cell and
proliferation marker expression coupled with telomerase
enzymatic activity, we find evidence for lower proliferation
levels in childhood ependymoma cell populations enriched
for stem cells (R. Rahman, unpublished findings). However
we cannot discriminate between a general reduced rate
of proliferation in the population as a whole or to the
existence of a quiescent subset within the total population. It
remains to be elucidated whether the aforementioned modes
of intrinsic GSCs are necessary and suﬃcient to achieve
intrinsic resistance in malignant glioma. The relationship
between the hypoxic glioma microenvironment and GSCs
may also impact upon future therapy as it has recently been
shown that HIF proteins are preferentially activated in GSCs
compared to nontumor cells [130]. Better understanding in
this respect will aid development of novel agents specifically
targeting GSCs.
5. Future Therapeutic Directions
The question of how to prolong the sometimes excellent
shortterm results of anti-angiogenic therapy is the subject of
much investigation. Current trials are focusing on combina-
tion approaches using multiple therapies to target diﬀerent
pathways concurrently with the hope of preventing the use
of diﬀerent pathways to evade the inhibition of a single
molecule. Novel agents are also underdevelopment which
will target the previously discussed pathways more eﬀectively,
and also with the aim of controlling mechanisms not yet fully
elucidated.
One promising new field that may yield eﬀective means
of controlling the angiogenic process is that of microRNAs.
These are short (20–23 base pair) conserved sequences that
are transcribed but not translated. First identified in C.
elegans in the early 1990s, it is only in the last 10 years
that their true importance has been recognized [56]. They
act by binding complementary sequences on messenger
RNA and interfering with (usually downregulating) the
translation of the mRNA into protein. There are now several
hundred recognised miRNA known to regulate human
gene translation, with approximately 50% of cancer related
genes having known miRNA regulators. High-grade gliomas
have characteristic profiles of miRNA expression [131–133],
and the diﬀerences between HGG, low-grade gliomas, and
normal tissue may give important clues as to how these short
RNA sequences control tumor growth and development,
including angiogenesis [134]. In other brain tumors such
as medulloblastoma [135], particular miRNAs have been
shown to be closely linked to the molecular machinery
driving the tumor. Various miRNA [136–138] have been
shown to be over or underexpressed in adult HGG with
changes in the particular miRNA identified profoundly
influencing glioma growth. miRNA has been shown to be
crucial to normal brain development [139, 140] and to the
processes of blood vessel creation and angiogenesis in normal
development [141] as well as in pathological processes such
as tumors. It has also been shown in glioma cell lines that
the upregulation of VEGF and other factors in response to
hypoxia may be governed by miRNA expression levels [142].
Therapeutically, it has been demonstrated that the eﬀect
of a particular miRNA can be strongly inhibited by engi-
neered oligonucleotide sequences, so-called “antagomirs”,
with consequent decreased levels of related protein synthesis
[143]. It has been demonstrated in a murine liver cancer
model that dramatic reduction in tumor burden can be
achieved by reactivating expression of miR-26a which is
down-regulated in liver cancer [144]. In human brain tumors
it has been shown that miR-296 is elevated in tumor-related
endothelial cells of new vessels and that this miRNA may
govern growth factor receptor expression [145]. It seems
likely that much work will focus on elucidating which are
the key miRNAs in GBM, how to antagonise/upregulate
them and on the delivery vectors that would be necessary
to use them in clinical trials [146]. A recent in vitro report
showed good activity against CD133+ glioma stem cells
by a combination of imatinib and the miRNA 451 [147].
Complete dispersion of neurospheres was observed at low
concentrations of the combined reagents.
5.1. Polymeric Controlled Release for Intracranial Drug Deliv-
ery. Over the past two decades, a variety of approaches
to enhance intracranial chemotherapeutic drug delivery
have been investigated. Local therapies (via injection) are
diﬀusion limited and may not reach areas distant to the site
of injection. One approach is polymeric-controlled release
for direct delivery of agents to intracranial tumors. The
rationale of such an approach is to improve upon the eﬃcacy
and reduce the debilitating side eﬀects of current systemic
chemotherapeutics. An attractive feature of biodegradable
polymers is that they completely erode during drug delivery
and are cleared from the body. The majority of biodegradable
polymers undergo erosion simply by water permeating into
the polymer matrix [148].
There are two main methods of utilising polymeric
controlled release for intracranial drug delivery: implantable
devices and nano- or microparticles for injection.
Implantable biodegradable polymeric devices provide a
practical means of localizing the chemotherapeutic agents
specifically at the tumor site. An additional advantage
of direct intracranial drug delivery is that the need for a
chemotherapeutic agent to cross the BBB is eliminated.
The most common copolymer system used intracra-
nially is polybis (p-carboxyphenoxy) propane-sebacic acid
(p (CPP-SA)). This delivery system has been characterized
for a variety of drugs and is in clinical use [149]. Many
controlled release systems are based on an implantable wafer.
The p(CPP-SA) wafer loaded with 1,3-bis (2-chloroethyl)-1-
nitrosourea (BCNU), also known as carmustine, is available
clinically as Gliadel [150]. Gliadel is implanted intracranially
after surgical debulking of the tumor. It is commonly used for
local delivery of BCNU to high-grade gliomas after resection
and is associated with increased survival [151]; however drug
diﬀusion from the site of implantation is limited.
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Implantable poly(lactic-co-glycolic acid) (PLGA) matri-
ces loaded with chemotherapeutics are currently under
development [149]. In an analogous method to Gliadel,
the use of biodegradable PLGA wafers containing BCNU
has been investigated and research in this area is ongoing
[152]. Biodegradable polymer matrices based on polymers
of lactide and glycolide are a popular platform for local
drug delivery. PLGA particles have been used as a controlled
delivery system for proteins, drugs, cytokines, hormones,
enzymes, vaccines, and chemotherapeutic agents [153–156].
The composition of the PLGA allows the control of the
degradation rate and therefore the control of drug release
kinetics [157].
In addition to controlled release via wafers, polymers
can also be harnessed to aid delivery of chemotherapeutic
drugs to the brain by injection of polymeric nano- or
microparticles. To date, minimally invasive systemic delivery
of drugs to the brain remains a challenge that has given
rise to the development of new drug-targeting technologies.
Many forms of systemic chemotherapy are excluded from
the central nervous system by the BBB and the high
systemic concentrations necessary to cross the BBB often
lead to several side eﬀects [158, 159]. The use of nano- or
microparticles for drug delivery to the brain appears to be a
promising option to overcome these problems.
The advantage of polymer particles lies in the route of
administration. Nano- or microparticles may be injected
stereotactically to any site in the brain due to their size
and spherical shape [160]. This is less invasive than the
implantation of polymeric wafers [149]. Recently, BCNU-
loaded PLGA microspheres were developed in vitro for
intracranial administration by cerebral stereotaxy, which
could potentially be administered repeatedly [161]. The use
of PLGA particles to deliver drugs other than BCNU is
also being investigated. Benny and colleagues demonstrated
the delivery of two endogenous anti-angiogenic inhibitors,
hemopexin (PEX) and a fragment of platelet factor 4 (PF-4)
(PF-4/CTF), in vitro and in vivo for human glioma therapy
using PLGA microspheres, with glioma growth inhibition
observed.
Over the last decade, coating polymeric particles with a
surfactant has also been investigated to enhance intravenous
delivery of chemotherapeutic drugs to the brain. As evi-
denced by a number of studies, poly(butyl cyanoacrylate)
(PBCA) nanoparticles coated with polysorbate 80 (Tween
80) facilitate brain delivery of a number of drugs that are
unable to cross the BBB in free form [162]. Polysorbate 80
also proved to be eﬀective for brain delivery of diﬀerent types
of nanoparticles such as poly (alkyl cyanoacrylate) and solid
lipid nanoparticles [163, 164]. Polysorbate 80-coated PBCA
nanoparticles have been found to selectively adsorb certain
plasma proteins from the blood. These proteins promote
receptor-mediated endocytosis of the polymer particles by
the endothelial cells forming the BBB, thus facilitating
delivery of the nanoparticle-encapsulated drug to the brain
[165].
The eﬀectiveness of the polysorbate 80-coated PBCA
nanoparticles for brain delivery was most clearly demon-
strated by the high antitumor eﬀect of nanoparticle-bound
doxorubicin against intracranial glioblastoma in rats [166].
A diﬀerent type of surfactant, poloxamer 188 (Pluronic F68),
was also found to be eﬀective for brain delivery by PBCA
particles [167, 168]. Recently, Gelperina and colleagues
showed that both polysorbate 80 and poloxamer 188 were
also able to facilitate brain delivery for PLGA nanoparticles
[169].
Harnessing polymeric controlled release in the form of
implants and injectable particles is proving to be a promising
area of investigation for intracranial drug delivery. Ongoing
and future research into this innovative drug delivery
method will strive to address the need for controllable
intracranial drug delivery for glioma therapy.
6. Summary and Perspectives
Although the transitory eﬃcacy of anti-angiogenic inhibitors
such as those targeting VEGF signalling pathways are
disappointing, with a temporary period of response fol-
lowed by relapse, these results must be considered in the
context of standard of care therapy for malignant glioma,
in particular GBM. These strategies also typically exhibit
an initial response followed by inevitable resistance and
tumor progression. Also, the majority of patient trials have
involved recurrent glioma tumors at a late-stage of disease
progression. Studies of anti-angiogenic therapies in patients
with newly diagnosed malignant glioma will help determine
whether these agents have greater eﬃcacy in an earlier
setting.
Approaches to overcome anti-angiogenic resistance may
include more potent anti-angiogenic agents, synergistic
strategies with drugs that inhibit other relevant targets,
or multi-targeted single agents that simultaneously inhibit
several crucial targets. The optimum protocol for the use
of anti-angiogenic therapy in combination with cytotoxic
chemotherapy and radiation therapy is as yet unclear for
gliomas and needs to be refined. The concept of a “window”
for increased therapeutic eﬀectiveness, opened by anti-
angiogenic therapy through normalization of vasculature, is
also being explored and may impact on regimes adopted in
future trials. Combination therapy with drugs that target
glioma invasion is a promising approach due to concerns
that anti-angiogenic therapy may lead to infiltrative tumor
growth. Furthermore, future modes of chemotherapeutic
delivery such as stereotactic injection of nanoparticles and
tumor site-specific implants concomitant with surgical resec-
tion may circumvent the ineﬃciency and reduce the toxicity
of systemic drug delivery and lead to a more targeted and
minimally invasive therapeutic approach to glioma.
Increasing evidence for the persistence of stem cell-
like cells in glioma may shift therapeutic approaches to
target these cell populations. With the elucidation of the
role of GSCs in glioma angiogenesis, it is tempting to
speculate that much of the observed intrinsic resistance
and non-responsiveness to anti-angiogenic therapies is due
to inherent properties of GSCs. We await a generation of
cytotoxic agents that specifically target glioma cells with
stem cell/progenitor properties. Combination strategies with
Journal of Oncology 11
such compounds and anti-angiogenic drugs may be an
exciting future avenue, where the latter mode of therapy
chemosensitizes the tumor prior to a direct cytotoxic hit on
GSCs.
A number of pertinent questions remain to be better
understood, answers of which will influence future modes
of therapy: are GSCs enriched in regions of hypoxia so
prevalent in GBM tumors? Is the cell type resistant to
anti-angiogenic therapy, the same cell type resistant to
chemotherapy and/or radiation therapy? What distinguishes
anti-angiogenic glioma cells with adaptive resistance and
those with intrinsic resistance? Can the same glioma cell type
within a given tumor exhibit both modes of anti-angiogenic
resistance and what are the implications for therapy if so?
What are the roles of bone marrow-derived cells and stromal
cells in the process of anti-angiogenic resistance? Are GSCs
involved in invasion, migration, and metastases and are such
cells the same GSCs that initiated the primary tumor?
Research into glioma tumor biology will be required to
identify novel targets amenable to anti-angiogenic therapy.
In conjunction, the development of novel methods for
chemotherapeutic delivery will continue to advance our
understanding of targeting tumor angiogenesis with wider
application for other solid tumors. Disruption of glioma
neovascularisation not only remains an attractive method of
intervention but provides a model to better overcome glioma
resistance.
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